Anti-PD-1 Immune Checkpoint Blockade for Head and Neck Cancer: Biomarkers of Response and Resistance

Otolaryngol Clin North Am. 2021 Aug;54(4):751-759. doi: 10.1016/j.otc.2021.04.006. Epub 2021 Jun 9.

Authors

Christopher A Maroun¹, Rajarsi Mandal²

Affiliations

¹ Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins University, Baltimore, MD 21287, USA; Bloomberg-Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, Baltimore, MD 21287, USA.
² Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins University, Baltimore, MD 21287, USA; Bloomberg-Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, Baltimore, MD 21287, USA. Electronic address: rmandal6@jhmi.edu.

PMID: 34116842
DOI: 10.1016/j.otc.2021.04.006

No abstract available

Keywords: Anti-PD-1; Biomarkers; Checkpoint blockade; Immunotherapy; Response.

Publication types

Review

MeSH terms

Antibodies, Monoclonal, Humanized
Biomarkers
Head and Neck Neoplasms / drug therapy*
Humans
Immune Checkpoint Inhibitors / therapeutic use*
Immunotherapy
Programmed Cell Death 1 Receptor

Substances

Antibodies, Monoclonal, Humanized
Biomarkers
Immune Checkpoint Inhibitors
Programmed Cell Death 1 Receptor